Sayers Craig, Mogford Daniel
Prison Healthcare, NHS Forth Valley, Stirling, Scotland, UK.
Camurus Ltd., Duxford, Cambridge, UK.
Subst Abuse Rehabil. 2025 Apr 15;16:83-93. doi: 10.2147/SAR.S510467. eCollection 2025.
To examine patient satisfaction with long-acting injectable buprenorphine (LAIB) as opioid agonist therapy (OAT) during custody, the effect on prisoner behavior and illicit drug use in custody, and the impact on healthcare utilization within OAT programs in Scottish prisons.
This observational, service evaluation included 134 adult patients (≥18 years) with opioid dependence. Clinically appropriate patients were stabilized on monthly LAIB. The following outcomes were evaluated at 12, 24, and 52 weeks: patient satisfaction using the Treatment Satisfaction Questionnaire for Medication (TSQM), patient-reported craving using a 100 mm visual analog scale (VAS), and opioid withdrawal using the Clinical Opiate Withdrawal Scale (COWS). Patient-reported illicit drug use and disciplinary actions were recorded.
Retention on LAIB for 12 months or until release/transfer was 93.8%. Patient satisfaction with LAIB was high, with median global TSQM scores >80 at all timepoints in the whole population and in those transferred after reduction from high-dose methadone (>30 mg/day). Compared with the first 4 weeks, craving significantly decreased at Weeks 12 and 24; the decrease at Week 52 was not statistically significant. COWS scores were also significantly lower at all timepoints. Levels of illicit drug use and disciplinary actions were low throughout. Healthcare worker contact time saved with LAIB versus methadone was estimated at ~100 minutes per patient monthly. As of June 30, 2024, ~228 hours in total are estimated to have been saved per month across the Forth Valley prison estate.
This service evaluation demonstrates high levels of patient satisfaction with LAIB in the prison setting, with minimal disruption to patient comfort or behavior even during treatment transition. Provision of LAIB has reduced healthcare hours required to deliver OAT medication in the Forth Valley prison estate, allowing the reprioritization of some healthcare resources toward other health-promoting goals.
研究在羁押期间,患者对长效注射用丁丙诺啡(LAIB)作为阿片类激动剂疗法(OAT)的满意度,其对囚犯在羁押期间行为及非法药物使用的影响,以及对苏格兰监狱OAT项目中医疗保健利用情况的影响。
这项观察性服务评估纳入了134名年龄≥18岁的阿片类药物依赖成年患者。临床适用的患者每月接受长效注射用丁丙诺啡治疗并实现病情稳定。在第12、24和52周评估以下结果:使用药物治疗满意度问卷(TSQM)评估患者满意度,使用100毫米视觉模拟量表(VAS)评估患者报告的渴望程度,使用临床阿片类药物戒断量表(COWS)评估阿片类药物戒断情况。记录患者报告的非法药物使用情况和纪律处分。
接受长效注射用丁丙诺啡治疗12个月或直至释放/转院的保留率为93.8%。患者对长效注射用丁丙诺啡的满意度较高,总体人群以及从高剂量美沙酮(>30毫克/天)减量后转用长效注射用丁丙诺啡的患者在所有时间点的TSQM中位数评分均>80。与前4周相比,在第12周和第24周渴望程度显著降低;第52周的降低无统计学意义。在所有时间点,临床阿片类药物戒断量表评分也显著更低。非法药物使用水平和纪律处分在整个过程中都较低。与美沙酮相比,使用长效注射用丁丙诺啡每名患者每月节省的医护人员接触时间估计约为100分钟。截至2024年6月30日,预计福斯谷监狱系统每月总共节省约228小时。
这项服务评估表明,在监狱环境中患者对长效注射用丁丙诺啡的满意度较高,即使在治疗转换期间对患者舒适度或行为的干扰也最小。提供长效注射用丁丙诺啡减少了福斯谷监狱系统提供OAT药物所需的医疗时间,使一些医疗资源能够重新分配用于其他促进健康的目标。